BJMO - 2024, issue Special, march 2024
A. Enguita PhD, T. Feys MBA, MSc
During the session entitled “Supportive care and setting up a trial” at BMUC 2024, Prof. Nele Devoogdt (UZ Leuven, Belgium) discussed current strategies to manage lymphoedema following pelvic therapies in cancer patients. Subsequently, Dr. Alastair Lamb (Oxford University, UK) talked about the factors that make clinical trial enrolment appealing to patients. Finally, Dr. Sanne D’hondt walked us through the necessary steps to set up a clinical trial.
Read moreBJMO - 2024, issue Special, march 2024
A. Enguita PhD
During the bladder cancer session at BMUC 2024; Prof. Ananya Choudhury (The University of Manchester, Manchester) underscored the necessity of reevaluating radiotherapy as a treatment for localised non-muscle invasive bladder cancer (NMIBC), underscoring its efficacy and safety also in elderly patients. Prof. Evanguelos Xylinas (Hôpital Bichat-Claude Bernard – APHP Nord, Paris) focused on emerging therapies for high-risk NMIBC patients unresponsive to Bacillus Calmette-Guérin treatment, such as intravesical gene therapy or immunotherapy. Finally, Prof. Sylvie Rottey (University Hospital Ghent, Ghent) discussed the pivotal Check-Mate-901 and EV-302 trials, which have transformed the first-line treatment of metastatic urothelial carcinoma.
Read moreBJMO - 2024, issue Special, february 2024
J. Blokken PhD, PharmD
In line with the tradition, the 2024 annual BSMO meeting kicked off with a session from the Breast Cancer Task Force. Dr. Françoise Derouane (University Hospitals Leuven, Leuven) opened the session with a lecture on candidates for neoadjuvant chemotherapy in luminal disease. Thereafter, Dr. Ines Nevelsteen (University Hospitals Leuven, Leuven) discussed targeted axillary dissection after neoadjuvant chemotherapy in cN+ disease. In a third lecture, Dr. Nuria Kotecki (Institut Jules Bordet, Brussels) addressed the current challenges in the approach of brain metastases in breast cancer. Finally, Dr. Kevin Punie (GZA Hospitals Sint-Augustinus, Wilrijk) shared his knowledge and experience on how to select the optimal adjuvant endocrine therapy in early HR+ breast cancer.
Read moreBJMO - 2024, issue Special, february 2024
A. Enguita PhD, T. Feys MBA, MSc
During the 2024 BSMO annual meeting, an entire session was dedicated to the recent advances in the treatment of gynaecological cancers. In a first lecture of this session, Prof. Dr. Christine Gennigens (CHU de Liège) gave an overview of the contemporary treatment landscape for patients with cervical cancer, after which Prof. Dr. Hannelore Denys (University Hospital Ghent), summarised the recent treatment advances and clinical updates in the treatment of endometrial cancer. To wrap up the session, Prof. Jean-François Baurain (UCLouvain) took the stage to provide an overview of the latest findings in the management of ovarian cancer.
Read moreBJMO - 2024, issue Special, february 2024
J. Blokken PhD, PharmD
The second day of the 2024 annual BSMO meeting kicked off with a session from the supportive care task force. First, Dr. Gary Deng (Memorial Sloan Kettering Cancer Center, United States) gave a talk on integrative medicine and how it helps cancer supportive care. Thereafter, Dr. Antonietta Iasiello (Dr. Spinedi Clinic, Orselina, Switzerland), discussed health education according to the Charter of Ottawa.
Read moreBJMO - 2024, issue Special, february 2024
J. Collins PhD
At the BMSO Annual Meeting 2024, Dr. Peter Vuylsteke (Medical Oncologist and Head of Department Internal Medicine at the University of Botswana) discussed the treatment disparities in oncological care and provided some suggestions on how to bridge this gap.1 Dr. Vuylsteke began by highlighting that not only is there a disparity in care between low- and middle-income countries (LMIC) and high-income countries (HIC), but disparities also arise due to the outbreak of war and epidemics such as COVID-19. Finally, regional differences in the quality of care exist.
Read moreBJMO - 2024, issue Special, february 2024
A. Enguita PhD
During the ‘What you should not have missed’ session at this year’s BSMO meeting, Prof. Dr. Awada from the Jules Bordet Institute revisited key treatment advances and clinical updates in oncology from 2023.
Read more
Top
